Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Preconditioning Single High-Dose Palifermin Alters the Posttransplant Inflammatory Cytokine Profile

Eduard Schulz, Noa G. Holtzman, Alen Ostojic, Filip Pirsl, Seth M. Steinberg, Lauren M. Curtis, Brian C. Shaffer, Theo Heller, Ashley Carpenter, Frances T. Hakim, Jeffrey S. Rubin, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 4788.

https://doi.org/10.1182/blood-2023-182284

Published: 2023

Journal Articles

Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Annie Im, Jacqueline Parkin, Noa G. Holtzman, William Moore, Lauren M. Curtis, Cody Peer, William D. Figg, Sr., Jeremy J. Rose, Laura Parsons-Wandell, Frances T. Hakim, Steven Z. Pavletic

Blood (2021) 138 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2021-151324

Published: 2021

Journal Articles

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Blood (2021) 137 (7): 896–907.

https://doi.org/10.1182/blood.2020006892

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Alen Ostojic, MD, Noa G. Holtzman, MD, Lauren M. Curtis, MD, Brian C. Shaffer, MD, Jeffrey S Rubin, MD PhD, Frances T. Hakim, PhD, Jacqueline W Mays, DDS, PhD, Theo Heller, MD, Edward W Cowen, MD, Sabine Werner, PhD, Michael Emanuel, BSN, RN, Seth M. Steinberg, PhD, Ronald E. Gress, MD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140059

Published: 2020

Journal Articles

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Annie Im, MD, Noa G. Holtzman, MD, Lauren M. Curtis, MD, Laura Parsons-Wandell, RN, Jeannette Nashed, BSN MSN CRNP, Cody Peer, PhD, William D. Figg, PhD, Amisha Barochia, MBBS, MHS, Jeremy J. Rose, MS, Frances T. Hakim, PhD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140481

Published: 2020

Journal Articles

Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study

Noa G. Holtzman, MD, Annie Im, MD, Alen Ostojic, MD, Lauren M. Curtis, MD, Laura Parsons-Wandell, RN, Jeannette Nashed, BSN MSN CRNP, Cody Peer, PhD, William D. Figg, Sr., PharmD, M. Teresa Magone, MD, Edward W Cowen, MD, Jacqueline W Mays, DDS, PhD, Frances T. Hakim, PhD, Jeremy J. Rose, MS, Marie C Pouzelles, PhD, Naomi Taylor, MD PhD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140392

Published: 2020

Journal Articles

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

Dana Schaar, Filip Pirsl, Seth M. Steinberg, PhD, Laura Parsons-Wandell, Michael Emanuel, Shaneil Flucker, Jeannette Nashed, Claire Ruben, Lauren M. Curtis, MD, Edward W Cowen, MD, Jacqueline Mays, PhD DDS, Pashna N. Munshi, MD, Annie Im, MD, Ann Berger, MD, Galen O Joe, MD, Manuel B Datiles, III, MD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 4558.

https://doi.org/10.1182/blood-2019-124020

Published: 2019

Journal Articles

A Large Cohort Comparison of 2005 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria to 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria

Blood (2017) 130 (Supplement 1): 4720.

https://doi.org/10.1182/blood.V130.Suppl_1.4720.4720

Published: 2017

Journal Articles

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Jennifer N. Brudno, MD, Victoria Shi, David Stroncek, MD, Stefania Pittaluga, MD PhD, Jennifer A. Kanakry, MD, Lauren M. Curtis, MD, Juan C. Gea-Banacloche, MD, Steven Pavletic, MD, Mohammad-Hadi Bagheri, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2016) 128 (22): 999.

https://doi.org/10.1182/blood.V128.22.999.999

Published: 2016

Journal Articles

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

Lauren M. Curtis, MD, David Venzon, PhD, Fran T. Hakim, PhD, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Licia Masuch, Jacqueline W. Mays, DDS, MHSc, PhD, Sandra A. Mitchell, CRNP, PhD AOCN, Filip Pirsl, Iskra Pusic, MD, Jeremy J. Rose, MS, Zoya J. Kuzmina, MD PhD, Kristin Baird, MD, Robert Peter Gale, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 507.

https://doi.org/10.1182/blood.V128.22.507.507

Published: 2016

Journal Articles

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Jacqueline W. Mays, DDS, MHSc, PhD, Lauren M. Curtis, MD, Carol Bassim, DMD, MS, Seth M. Steinberg, PhD, David Venzon, PhD, Jeremy J. Rose, MS, Monica Cho, Christopher G. Kanakry, MD, Fahd Yazdanie, Daniele Avila, NP, Kristin Baird, MD, Jennifer Hsu, RN, Licia Masuch, George Grimes, RPh, Judith Starling, RPh, Daniel H. Fowler, MD, Ronald E. Gress, MD, Fran T. Hakim, PhD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 826.

https://doi.org/10.1182/blood.V128.22.826.826

Published: 2016

Journal Articles

IL-2, the next best thing in chronic GVHD therapy?

Lauren M. Curtis, Steven Z. Pavletic

Blood (2016) 128 (1): 13–15.

https://doi.org/10.1182/blood-2016-05-711796

Published: 2016

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Annie Im, MD, Frances T. Hakim, PhD, Filip Pirsl, Seth M. Steinberg, PhD, Lauren M. Curtis, MD, Sandra A. Mitchell, CRNP, PhD AOCN, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Judy Baruffaldi, Licia Masuch, Juan C. Gea-Banacloche, MD, David C. Halverson, MD, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2015) 126 (23): 1937.

https://doi.org/10.1182/blood.V126.23.1937.1937

Published: 2015

NARROW

Preconditioning Single High-Dose Palifermin Alters the Posttransplant Inflammatory Cytokine Profile

Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

A Large Cohort Comparison of 2005 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria to 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

IL-2, the next best thing in chronic GVHD therapy?

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only